On March 13, 2026, Novartis announced that the FDA granted approval for COSENTYX (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa (HS) in pediatric patients aged 12 years and older weighing at least 30 kg. The approval marks the fourth pediatric indication for COSENTYX and, critically, establishes it as the only IL-17A inhibitor approved for this age group, extending Novartis’s biologic portfolio into a segment where therapeutic choices have historically been extremely limited.
Secukinumab Clinical Evidence Underpinning the Approval
The FDA’s decision was primarily supported by efficacy and pharmacokinetic data extrapolated from the pivotal SUNSHINE and SUNRISE Phase III clinical trials, which enrolled 676 and 687 adult hidradenitis suppurativa patients respectively (mean age 36.1 years). Key findings included:
-
Achievement of HiSCR50 (at least 50% reduction in abscess and inflammatory nodule count, with no increase in abscesses or draining tunnels) at a significantly higher proportion versus placebo in both trials.
-
Onset of action observed as early as Week 2, with statistically significant separation from placebo maintained at Week 16.
-
Consistent efficacy regardless of prior biologic therapy experience, covering both biologic-naive and biologic-experienced patient populations.
-
Pediatric dosing based on weight-based pharmacokinetic modeling (≥30 kg), validated to achieve drug exposure levels comparable to those in successful adult trials.
The approval follows COSENTYX’s initial FDA clearance for adult HS in 2023, which made it the first IL-17A inhibitor in the indication. The pediatric extension in 2026 now closes a meaningful gap in the treatment algorithm for adolescents, a population where hidradenitis suppurativa onset is most common.
For detailed analysis on this, visit Secukinumab Clinical trials Analysis
Understanding Hidradenitis Suppurativa: The Disease Burden
Hidradenitis suppurativa is a chronic, systemic, progressive inflammatory skin disease characterized by recurring boil-like abscesses in the intertriginous regions — armpits, groin, and under breasts — that rupture, drain, and scar. It is estimated to affect approximately 1% of the global population, though some prevalence estimates range as high as 4%, with significant underdiagnosis complicating accurate measurement.
Hidradenitis Suppurativa carries a disproportionately high disease burden:
-
Onset typically occurs around puberty: more than half of all patients develop their first symptoms during their teenage years.
-
Diagnosis is frequently delayed by an average of up to 10 years from symptom onset, allowing significant irreversible damage in the interim.
-
Hidradenitis suppurativa impacts quality of life more severely than nearly any other dermatological condition, with comorbidities including obesity, diabetes, arthritis, and depression.
-
The pediatric population faces additional developmental consequences: scarring, chronic pain, and stigma during formative years with lasting psychological impact.
Hidradenitis Suppurativa Market Analysis
The hidradenitis suppurativa treatment market demonstrated strong commercial momentum entering the forecast period. The US represents by far the largest single market, accounting for the majority of the ~USD 1.5 billion 7MM market size. The market is forecast to grow at a significant CAGR through 2036, driven by label expansions such as COSENTYX’s pediatric approval, increasing biologic penetration, and a robust incoming pipeline.
Hidradenitis Suppurativa Treatment Landscape & Competitive Dynamics
Historically, hidradenitis suppurativa was managed with topical and systemic antibiotics, corticosteroids, and surgical procedures such as deroofing and excision. The biologic era transformed moderate-to-severe management:
-
HUMIRA (adalimumab, AbbVie): The first and long-standing biologic approved for HS in adults and, since 2018, for adolescents aged 12+. Biosimilar pressure (including AMJEVITA’s 2023 US launch) has meaningfully eroded HUMIRA’s market share.
-
COSENTYX (secukinumab, Novartis): First approved for adult HS in 2023 as the first IL-17A inhibitor in the indication, and now expanded to pediatric patients.
-
BIMZELX (bimekizumab, UCB): Approved in Europe for HS but pending US sBLA review as of April 2024. Bimekizumab’s dual IL-17A/IL-17F inhibition has shown “incrementally better” clinical outcomes versus COSENTYX in comparative analyses, posing a medium-term competitive threat in the adult segment.
Dive deeper into this evolving landscape @ Hidradenitis Suppurativa Treatment Landscape Analysis
Hidradenitis Suppurativa Pipeline Intelligence: What Comes Next
The hidradenitis suppurativa therapeutic pipeline is among the most active in dermatology, with multiple agents across novel mechanisms in Phase II/III development. Key candidates with potential to reshape market dynamics include:
-
Povorcitinib, developed by Incyte Corporation, is an oral JAK1 inhibitor currently in Phase III clinical development.
-
Sonelokimab, being developed by MoonLake Immunotherapeutics, is an IL-17A/F nanobody in Phase II/III trials.
-
Spesolimab, from Boehringer Ingelheim, targets the IL-36 receptor (IL-36R) and is in Phase II clinical studies.
-
Lutikizumab, developed by AbbVie, is an IL-1α/β inhibitor currently undergoing Phase II clinical evaluation.
-
Eltrekibart, being investigated by Eli Lilly, targets the IL-1 pathway and is in Phase II development.
-
Orismilast, developed by UNION Therapeutics, is an oral PDE4 inhibitor being evaluated in Phase II trials for mild hidradenitis suppurativa.
Notably, Povorcitinib (Incyte) is positioned to become the first approved oral therapy for HS, with clinical outcomes that reportedly outperform RINVOQ in head-to-head analyses. Sonelokimab’s dual IL-17A/F inhibition has generated significant enthusiasm given nanobody technology advantages in tissue penetration, its Phase III replication will be closely watched for potential displacement of secukinumab in the adult segment.
For in-depth Pipeline Intelligence: Hidradenitis Suppurativa Emerging Drug Insight & Market Forecast
Strategic Implications for Pharma Executives
The pediatric Hidradenitis Suppurativa label expansion is a strategically significant move for Novartis across multiple dimensions:
-
First-mover exclusivity in an underserved demographic: COSENTYX is now the only biologic offering an IL-17A-targeted option for adolescents, a population where only adalimumab (with biosimilar pressure) previously held a label.
-
Label breadth reinforcement: With four pediatric indications (HS, psoriasis, ERA, JPsA), COSENTYX cements its position as the most broadly labeled IL-17A inhibitor across age groups.
-
Revenue floor defense: Biosimilars have progressively eroded Novartis’s adult hidradenitis suppurativa market share in multiple geographies. The pediatric expansion opens a new revenue segment with limited biosimilar competition given the additional clinical development requirements for pediatric use.
-
Lifecycle management optics: The approval strengthens COSENTYX’s product lifecycle ahead of the broader biologic patent cliff, signaling ongoing innovation commitment to payers and prescribers.
-
Despite HUMIRA’s established adolescent hidradenitis suppurativa label (2018), biosimilar erosion means COSENTYX’s differentiated IL-17A mechanism could attract payers seeking newer modality coverage. AbbVie’s pipeline (Lutikizumab) offers a potential next-gen alternative.
-
Its dual IL-17A/F profile with reportedly better efficacy is BIMZELX’s competitive differentiator, but a pediatric label is not yet in place. Racing to close this gap will be a commercial priority.
-
For Pipeline companies: Povorcitinib’s oral route and Sonelokimab’s superior tissue penetration each represent differentiated value propositions. The pediatric segment, now validated by COSENTYX, may attract expedited development strategies.
Benchmark Secukinumab Competitor Strategies @ Hidradenitis Suppurativa Competitive Landscape
Hidradenitis Suppurativa Unmet Needs and Market Opportunity
Despite this landmark approval, substantial unmet medical need persists across the HS population:
-
Mild HS segment: No approved pharmacotherapy exists for mild HS as of the date of this release. This segment remains entirely untapped by biologics, with only orismilast and ruxolitinib cream in early investigation.
-
Long-term durability data in adolescents: All current pediatric efficacy data in HS is extrapolated from adult trial endpoints. Real-world pediatric-specific long-term data will be required by regulators and payers going forward.
-
Diagnosis gap: The average delay to correct diagnosis of ~10 years means the addressable treated population remains a fraction of the true prevalent population, representing a market access and medical education opportunity.
-
Biologic-refractory patients: A meaningful subset of moderate-to-severe HS patients do not achieve or sustain adequate response on existing biologics, driving demand for novel mechanisms such as JAK inhibitors and nanobodies.
Quantify the Unmet Need Opportunity: Request the Hidradenitis Suppurativa Epidemiology & Market Analysis Report
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services